NexBio welcomes inquiries regarding collaboration opportunities. Our present partnering focus is as follows:

Fludase^®: NexBio is seeking a corporate partner to assist with the funding, development and commercialization of the Fludase program. NexBio will collaborate and invest as an equal partner. Specific details of territory, field of use, and commercial rights and responsibilities will depend on the capabilities of the partner. Throughout, the aim will be to fulfill the potential of this important new approach to Influenza-Like Illness.

TOSAP^® Platform: NexBio offers TOSAP to third parties per a licensing model.  Paid feasibility studies are offered.  Formulation development on compounds of interest is completed in-house at the NexBio facility in San Diego, CA.  Once completed, the technology is transferred to the client or to a designated third party manufacturer, under license.

For further information, please contact:

David Wurtman
VP, Corporate Development
(858) 452-2631
This e-mail address is being protected from spambots. You need JavaScript enabled to view it